Fig. 2From: Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypesImpact of guselkumab and adalimumab treatment on activated Th1 and activated Th17 cells. The proportion of A activated Th1 cells to CD3+ and CD4+ T cells (%) and B activated Th17 cells to CD3+ and CD4+ T cells (%). *p<0.05, by Wilcoxon signed-rank testBack to article page